Methods of treating cerebral amyloid angiopathy

1. A method of treating Cerebral Amyloid Angiopathy (CAA) in a subject, the method comprising:

identifying a subject who has been diagnosed with CAA but who has not been diagnosed with Alzheimer's Disease;

selecting the subject on the basis that they have CAA; and

nasally administering a therapeutically effective amount of a proteosome-based adjuvant to the identified subject.

2. The method of claim 1 , further comprising diagnosing the subject with CAA.

3. The method of claim 2 , wherein the diagnosis of CAA is made according to the Boston Cerebral Amyloid Angiopathy Group guidelines.

4. The method of claim 2 , wherein the diagnosis is made based on the presence of a single lobar, cortical, or corticosubcortical hemorrhage without another cause, multiple hemorrhages with a possible but not a definite cause, or a hemorrhage in an atypical location.

5. The method of claim 1 , further comprising administering one or more clinical tests to evaluate the effectiveness of the treatment.

6. The method of claim 5 , wherein the clinical tests include one or more imaging studies.

7. The method of claim 5 , wherein the clinical tests include a cognitive evaluation.

8. The method of claim 1 , further comprising administering one or more treatments for CAA.

9. The method of claim 8 , wherein the one or more treatments include surgical hematoma evacuation, or administration of a pharmaceutical.

10. A method of decreasing risk of recurrence of intracranial hemorrhage (ICH) in a subject who has had at least one diagnosed ICH and who has not been diagnosed with Alzheimer's Disease, the method comprising: identifying a subject who has had at least one diagnosed ICH, and nasally administering a therapeutically effective amount of a proteosome-based adjuvant to the identified subject.

11. The method of claim 9 , wherein the pharmaceutical is a corticosteroid or cyclophosphamide.